Drugs / TD-8236
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT03652038 | Nov 2018 → Jul 2020 | asthma | Theravance Biopharma | Completed | Met primary |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04150341 | Nov 2019 → Aug 2020 | asthma | Theravance Biopharma | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-09 | Theravance Biopharma | Results Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases theravance.com ↗
Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced initial results, including positive biomarker responses, from its Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial of TD-8236, an investigational, lung-selective inhaled pan-Janus kinase (JAK) inhibitor for inflammatory lung diseases. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD-8236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04150341 ↗ |
| Route | Inhaled | “Study drug to be administered via inhaler device” NCT03652038 ↗ |